Stockreport

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF Patients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-we [Read more]